• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Siga Technologies touts pivotal data for oral smallpox therapy

July 5, 2018 By Sarah Faulkner

SIGA Technologies logoSiga Technologies (NSDQ:SIGA) said today that data from a pivotal human safety study and animal efficacy studies of its oral smallpox therapy were published in the New England Journal of Medicine.

Data from the studies support the efficacy and favorable safety profile of Tpoxx, an oral formulation of tecovirimat.

“Smallpox is both highly contagious and highly lethal and there is growing concern that smallpox could be used as a potential bioweapon,” CEO Phil Gomez said in prepared remarks. “A smallpox bioterror attack could be especially damaging because the majority of today’s population is not immune to the virus, as routine vaccination ended in the 1970s. Rapid spread from person-to-person can occur through speaking, breathing or touching, and smallpox also can be transmitted by direct contact with infected fluids and contaminated objects.  These factors underscore the need for an effective smallpox antiviral therapy, and we believe that Tpoxx can address this need.”

Researchers assessed the efficacy of Tpoxx in non-human primate and rabbit models of smallpox. The treatment was also evaluated in a placebo-controlled human pharmacokinetic and safety study that enrolled 449 adult volunteers.

“The human safety and animal efficacy data reported in the New England Journal of Medicine are a large part of the Tpoxx new drug application and support the use of this novel antiviral agent,” Dennis Hruby, senior author and chief scientist at SIGA, added. “The absence of drug-related serious adverse events in the human safety trial coupled with a high survival rate in Tpoxx-treated non-human primates receiving a lethal challenge dose of monkeypox virus establish a compelling risk-benefit profile for Tpoxx in the treatment of smallpox.”

Siga filed a new drug application for Tpoxx with the FDA in December. Earlier this year, the FDA’s antimicrobial drugs advisory committee voted unanimously that the benefits of Tpoxx outweigh its risks.

The FDA is slated to make a decision whether or not to approve oral Tpoxx by August 8. SIGA shares were trading at $6.26 apiece in mid-afternoon activity today, up +3.7%.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Clinical Trials, Featured, Pharmaceuticals, Wall Street Beat Tagged With: sigatechnologies

IN CASE YOU MISSED IT

  • Abbott could pave new roads in diabetes management with dual sensor on the horizon
  • Tandem Diabetes Care pairs t:slim X2 pump with Abbott FreeStyle Libre 3 Plus in U.S.
  • Ypsomed, CamDiab to integrate Abbott dual glucose-ketone sensor into automated insulin delivery system
  • PharmaSens, SiBionics collab on all-in-one insulin patch pump
  • Beta Bionics to pair iLet automated insulin delivery system with Abbott’s dual glucose-ketone sensor

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS